Should Pharmacies Keep Compounding GLP1s?
DiversifyRx
APRIL 29, 2025
Deadlines For Compounding GLP1s (Semaglutide & Tirzepatide) Stay up to date on the FDA’s opinion at their website HERE. 503As must stop compounding GLP1s as of April 24, 2025. While 503Bs must stop by May 22, 2025 Tirzepatide: Injunction denied. 503As must stop compounding GLP1s as of March 5, 2025.
Let's personalize your content